Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Deborah Collyar: What's In It for Patients?

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Aug
25
Today In Oncology
Metabolic Syndrome Frequently Documented During First Year of ADT-ARPI Therapy in Prostate Cancer
The Mid-Career Oncologist in LMIC Regions: Navigating Disparities, Avoiding Burnout, and Delivering Optimal Care
Long-Term Survivors of Hodgkin Lymphoma May Face Elevated Health Risks, Study Finds
Preoperative Weight-Loss Program Shows Feasibility Before Endometrial Cancer Surgery
ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo